Actively Recruiting
Phase 1 Clinical Trial Evaluating Safety, Tolerability, and Immune Response of VAX-A1 Vaccine in Healthy Adults Aged 18 to 40
Led by Vaxcyte, Inc. · Updated on 2026-06-16
80
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a phase 1, first-in-human, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, and immune response of the VAX-A1 vaccine in healthy adults aged 18 to 40 years. The study aims to understand how the vaccine affects the immune system and monitor any side effects in this healthy young adult population. Participants are assigned to one of four groups receiving either low, mid, or high doses of VAX-A1 or placebo. Each participant receives two intramuscular injections, one on Day 1 and another at Month 2. The study follows a dose-escalation design to carefully evaluate different vaccine doses compared to placebo. Throughout the study, participants will be closely monitored for local and systemic reactions up to 7 days after each vaccination, as well as any adverse events for up to 8 months after the first dose. Blood samples will be collected at multiple time points to evaluate immune responses and safety laboratory tests. Participants will also complete an electronic diary to help track symptoms and reactions, with follow-up visits continuing through the study duration until 6 months after the second dose.
CONDITIONS
Brief Title
A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-A1 in Healthy Young Adults
Research Team
C
Clinical Development
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here